Management of precancerous conditions and lesions in the stomach (MAPS): Guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED)

Endoscopy

Volumn 44, Issue 1, 2012, Pages 74-94

  Dinis Ribeiro, M ^a,e   Areia, M ^b,e   De Vries, A C ^c   Marcos Pinto, R ^d,f   Monteiro Soares, M ^e   Oconnor, A ^g   Pereira, C ^a   Pimentel Nunes, P ^a   Correia, R ^e   Ensari, A ^h   Dumonceau, J M ⁱ   MacHado, J C ^f   MacEdo, G ^d   Malfertheiner, P ^j   Matysiak Budnik, T ^k   Megraud, F ^l   Miki, K ^m   Omorain, C ^g   Peek, R M ⁿ   Ponchon, T ^o   Ristimaki, A ^p,q   Rembacken, B ^r   Carneiro, F ^f,s   Kuipers, E J ^c   more..

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b Instituto Portugues de Oncologia Francisco Gentil Centro Regional de Oncologia de Coimbra SA   (Portugal)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Institute of Biomedical Sciences Abel Salazar   (Portugal)

^e University of Porto   (Portugal)

^f UNIVERSITY OF PORTO   (Portugal)

^g ADELAIDE AND MEATH HOSPITAL   (Ireland)

^h ANKARA UNIVERSITY   (Turkey)

ⁱ Hôpital Cantonal   (Switzerland)

^j OTTO VON GUERICKE UNIVERSITY   (Germany)

^k HÔTEL DIEU   (France)

^l UNIVERSITÉ DE BORDEAUX   (France)

^m Japan Research Foundation of Prediction   (Japan)

ⁿ VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o EDOUARD HERRIOT HOSPITAL   (France)

^p HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^q UNIVERSITY OF HELSINKI   (Finland)

^r LEEDS GENERAL INFIRMARY   (United Kingdom)

^s Universidade do Porto   (Portugal)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; ATROPHIC GASTRITIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER RISK; CANCER STAGING; CARCINOGENESIS; ERADICATION THERAPY; GASTROINTESTINAL ENDOSCOPY; HEALTH CARE COST; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTESTINE METAPLASIA; PORTUGAL; PRACTICE GUIDELINE; PRECANCER; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; STOMACH BIOPSY;

BIOPSY; EVIDENCE-BASED MEDICINE; GASTRIC MUCOSA; GASTRITIS, ATROPHIC; GASTROSCOPY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METAPLASIA; PEPSINOGENS; POPULATION SURVEILLANCE; PRECANCEROUS CONDITIONS; STOMACH NEOPLASMS;

EID: 84055214072     PISSN: 0013726X     EISSN: 14388812     Source Type: Journal    
DOI: 10.1055/s-0031-1291491     Document Type: Article

References (271)

1. Correa P. A human model of gastric carcinogenesis. Cancer Res: 1988; 48 3554 3560
2. Collaboration AGREE Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care: 2003; 12 18 23
3. Atkins D, Best D, Briss PA. et al. GRADE Working Group Grading quality of evidence and strength of recommendations. BMJ: 2004; 328 1490
4. Guyatt GH, Oxman AD, Vist GE. et al. GRADE working group GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ: 2008; 336 924 926 (Pubitemid 351632017)
5. Harbour R, Miller J. A new system for grading recommendations in evidence-based guidelines. BMJ: 2001; 323 334 336 (Pubitemid 32744465)
6. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res: 1992; 52 6735 6740 (Pubitemid 23006271)
7. Kapadia CR. Gastric atrophy, metaplasia and dysplasia. A clinical perspective. J Clin Gastroenterol: 2003; 36 29 36
8. Carneiro F, Machado JC, David L et al. Current thoughts on the histopathogenesis of gastric cancer. Eur J Cancer Prev: 2001; 10 101 102 (Pubitemid 32200209)
9. Ihamki T, Saukkonen M, Siurala M. Long term observation of subjects with normal mucosa and with superficial gastritis: results of 2327 years follow-up examination. Scand J Gastroenterol: 1978; 13 771 775 (Pubitemid 9067120)
10. Ormiston MC, Gear MW, Codling BW. Five year follow-up study of gastritis. J Clin Pathol: 1982; 35 757 760 (Pubitemid 12092663)
11. Laurn P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand: 1965; 64 31 49
12. Fukao A, Hisamichi S, Ohsato M et al. Correlation between the prevalence of gastritis and gastric cancer in Japan. Cancer Causes Control: 1993; 4 17 20 (Pubitemid 23051893)
13. Genta RM. Review article: gastric atrophy and atrophic gastritisnebulous concepts in search of a definition. Aliment Pharmacol Ther: 1998; 12 17 23
14. Dixon MF, Genta RM, Yardley JH et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol: 1994; 20 1161 1181
15. Misiewicz JJ. The Sydney System: a new classification of gastritis. Introduction. J Gastroenterol Hepatol: 1991; 6 207 208
16. Plummer M, Buiatti E, Lopez G et al. Histological diagnosis of precancerous lesions of the stomach: a reliability study. Int J Epidemiol: 1997; 26 716 720 (Pubitemid 27367846)
17. Filipe MI, Potet F, Bogomoletz WV et al. Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres. Gut: 1985; 26 1319 1326 (Pubitemid 16134454)
18. Filipe MI, Barbatis C, Sandey A et al. Expression of intestinal mucin antigens in the gastric epithelium and its relationship with malignancy. Hum Pathol: 1988; 19 19 26 (Pubitemid 18065866)
19. Silva S, Filipe MI, Pinho A. Variants of intestinal metaplasia in the evolution of chronic atrophic gastritis and gastric alcer. A follow up study. Gut: 1990; 31 1097 1104 (Pubitemid 20343047)
20. Reis CA, David L, Correa P et al. Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC and MUC6) expression. Cancer Res: 1999; 59 1003 1007 (Pubitemid 29135958)
21. Gutirrez-Gonzlez L, Wright NA. Biology of intestinal metaplasia in 2008: more than a simple phenotypic alteration. Dig Liver Dis: 2008; 40 510 522
22. Correa P. Clinical implications of recent developments in gastric cancer pathology and epidemiology. Semin Oncol: 1985; 12 2 10 (Pubitemid 15101318)
23. Genta RM, Rugge M. Gastric precancerous lesions: heading for an international consensus. Gut: 1999; 45 15 18
24. Guindi M, Riddell RH. The pathology of epithelial pre-malignancy of the gastrointestinal tract. Best Pract Res Clin Gastroenterol: 2001; 15 191 210 (Pubitemid 32573852)
25. Riddell RH. Premalignant and early malignant lesions in the gastrointestinal tract: definitions, terminology and problems. Am J Gastroenterol: 1996; 91 864 872 (Pubitemid 26143521)
26. Odze RD, Riddell RH, Bosman FT. et al. (ed.) Premalignant lesions of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND. (ed) WHO Classification of Tumours of the Digestive System. 4 edn. Lyon IARC Press: 2010
27. Park SY, Jeon SW, Jung MK et al. Long-term follow-up study of gastric intraepithelial neoplasias: progression from low-grade dysplasia to invasive carcinoma. Eur J Gastroenterol Hepatol: 2008; 20 966 970
28. de Vries AC, van Grieken NC, Looman CW et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology: 2008; 134 945 952 (Pubitemid 351451990)
29. Yamada H, Ikegami M, Shimoda T et al. Long-term follow-up study of gastric adenoma/dysplasia. Endoscopy: 2004; 36 390 396 (Pubitemid 38578884)
30. Dinis-Ribeiro M, Lopes C, da Costa-Pereira A et al. A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia. J Clin Pathol: 2004; 57 177 182 (Pubitemid 38177758)
31. Whiting JL, Sigurdsson A, Rowlands DC et al. The long term results of endoscopic surveillance of premalignant gastric lesions. Gut: 2002; 50 378 381 (Pubitemid 34161055)
32. You WC, Li JY, Blot WJ et al. Evolution of precancerous lesions in a rural Chinese population at high risk of gastric cancer. Int J Cancer: 1999; 83 615 619 (Pubitemid 29508039)
33. Kokkola A, Haapiainen R, Laxn F et al. Risk of gastric carcinoma in patients with mucosal dysplasia associated with atrophic gastritis: a follow-up study. J Clin Pathol: 1996; 49 979 984 (Pubitemid 27273808)
34. Rugge M, Farinati F, Baffa R et al. Gastric epithelial dysplasia in the natural history of gastric cancer: a multicenter prospective follow-up study. Interdisciplinary Group on Gastric Epithelial Dysplasia. Gastroenterology: 1994; 107 1288 1296 (Pubitemid 24328264)
35. Bearzi I, Brancorsini D, Santinelli A et al. Gastric dysplasia: a ten-year follow-up study. Pathol Res Pract: 1994; 190 61 68 (Pubitemid 24106587)
36. Di Gregorio C, Morandi P, Fante R et al. Gastric dysplasia. a follow-up study. Am J Gastroenterol: 1993; 88 1715 1719
37. Fertitta AM, Comin U, Terruzzi V et al. Clinical significance of gastric dysplasia: a multicenter follow-up study. Gastrointestinal Endoscopic Pathology Study Group. Endoscopy: 1993; 25 265 268 (Pubitemid 23184553)
38. Farinati F, Rugge M, Di Mario F et al. Early and advanced gastric cancer in the follow-up of moderate and severe gastric dysplasia patients. A prospective study. I.G.G.E.D. Interdisciplinary Group on Gastric Epithelial Dysplasia. Endoscopy: 1993; 25 261 264 (Pubitemid 23184552)
39. Rugge M, Farinati F, Di Mario F et al. Gastric epithelial dysplasia: a prospective multicenter follow-up study from the Interdisciplinary Group on Gastric Epithelial Dysplasia. Hum Pathol: 1991; 22 1002 1008
40. Rugge M, Baffa R, Farinati F et al. Epithelial dysplasia in atrophic gastritis. Bioptical follow-up study. Ital J Gastroenterol: 1991; 23 70 73
41. Koch HK, Oehlert M, Oehlert W. An evaluation of gastric dysplasia in the years 1986 and 1987. Pathol Res Pract: 1990; 186 80 84 (Pubitemid 20097949)
42. Lansdown M, Quirke P, Dixon MF et al. High grade dysplasia of the gastric mucosa: a marker for gastric adenocarcinoma. Gut: 1990; 31 977 983 (Pubitemid 20295928)
43. Coma del Corral MJ, Pardo-Mindan FJ, Razquin S et al. Risk of cancer in patients with gastric dysplasia. Follow-up study of 67 patients. Cancer: 1990; 65 2078 2085 (Pubitemid 20147652)
44. Correa P, Haenszel W, Cuello C et al. Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res: 1990; 50 4737 4740 (Pubitemid 20230422)
45. Saraga EP, Gardiol D, Costa J. Gastric dysplasia. A histological follow-up study. Am J Surg Pathol: 1987; 11 788 796 (Pubitemid 17143585)
46. Andersson AP, Lauritsen KB, West F et al. Dysplasia in gastric mucosa: prognostic significance. Acta Chir Scand: 1987; 153 29 31 (Pubitemid 17038261)
47. Aste H, Sciallero S, Pugliese V et al. The clinical significance of gastric epithelial dysplasia. Endoscopy: 1986; 18 174 176 (Pubitemid 16014614)
48. Farini R, Pagnini CA, Farinati F et al. Is mild gastric epithelial dysplasia an indication for follow-up? J Clin Gastroenterol: 1983; 5 307 310 (Pubitemid 13073842)
49. Riddell RH, Goldman H, Ransohoff DF et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol: 1983; 14 931 968
50. Lauwers GY, Shimizu M, Correa P et al. Evaluation of gastric biopsies for neoplasia: differences between Japanese and Western pathologists. Am J Surg Pathol: 1999; 23 511 518 (Pubitemid 29214952)
51. Lauwers GY, Carneiro F, Graham DY et al. Gastric carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND. (eds.) WHO Classification of tumours of the digestive system. 4 edn. Lyon IARC Press: 2010; 48 58
52. Atkins L, Benedict EB. Correlation of gross gastroscopic findings with gastroscopic biopsy in gastritis. N Engl J Med: 1956; 254 641 644
53. Bah A, Saraga E, Armstrong D et al. Endoscopic features of Helicobacter pylori-related gastritis. Endoscopy: 1995; 27 593 596
54. Calabrese C, Di Febo G, Brandi G et al. Correlation between endoscopic features of gastric antrum, histology and Helicobacter pylori infection in adults. Ital J Gastroenterol Hepatol: 1999; 31 359 365 (Pubitemid 29366663)
55. Carpenter HA, Talley NJ. Gastroscopy is incomplete without biopsy: clinical relevance of distinguishing gastropathy from gastritis. Gastroenterology: 1995; 108 917 924
56. Loffeld RJ. Diagnostic value of endoscopic signs of gastritis: with special emphasis to nodular antritis. Neth J Med: 1999; 54 96 100 (Pubitemid 29114981)
57. Reden S, Petersson F, Jnsson KA et al. Relationship of gastroscopic features to histological findings in gastritis and Helicobacter pylori infection in a general population sample. Endoscopy: 2003; 35 946 950 (Pubitemid 37368820)
58. Stathopoulos G, Goldberg RD, Blackstone MO. Endoscopic diagnosis of intestinal metaplasia. Gastrointest Endosc: 1990; 36 544 545 (Pubitemid 20349160)
59. Eshmuratov A, Nah JC, Kim N et al. The correlation of endoscopic and histological diagnosis of gastric atrophy. Dig Dis Sci: 2010; 55 1364 1375
60. Yan SL, Wu ST, Chen CH et al. Mucosal patterns of Helicobacter pylori-related gastritis without atrophy in the gastric corpus using standard endoscopy. World J Gastroenterol: 2010; 16 496 500
61. Laine L, Cohen H, Sloane R et al. Interobserver agreement and predictive value of endoscopic findings for H. pylori and gastritis in normal volunteers. Gastrointest Endosc: 1995; 42 420 423
62. Dinis-Ribeiro M, da Costa-Pereira A, Lopes C et al. Magnification chromoendoscopy for the diagnosis of gastric intestinal metaplasia and dysplasia. Gastrointest Endosc: 2003; 57 498 504 (Pubitemid 36402715)
63. Areia M, Amaro P, Dinis-Ribeiro M et al. External validation of a classification for methylene blue magnification chromoendoscopy in premalignant gastric lesions. Gastrointest Endosc: 2008; 67 1011 1018 (Pubitemid 351728107)
64. Mouzyka S, Fedoseeva A. Chromoendoscopy with hematoxylin in the classification of gastric lesions. Gastric Cancer: 2008; 11 15 21 discussion 2122 (Pubitemid 351464477)
65. Tanaka K, Toyoda H, Kadowaki S et al. Surface pattern classification by enhanced magnification endoscopy for identifying early gastric cancers. Gastrointest Endosc: 2008; 67 430 437 (Pubitemid 351253651)
66. Anagnostopoulos GK, Yao K, Kaye P et al. High-resolution magnification endoscopy can reliably identify normal gastric mucosa, Helicobacter pylori-associated gastritis, and gastric atrophy. Endoscopy: 2007; 39 202 207 (Pubitemid 46510790)
67. Gonen C, Simsek I, Sarioglu S et al. Comparison of high resolution magnifying endoscopy and standard videoendoscopy for the diagnosis of Helicobacter pylori gastritis in routine clinical practice: a prospective study. Helicobacter: 2009; 14 12 21
68. Tahara T, Shibata T, Nakamura M et al. Gastric mucosal pattern by using magnifying narrow-band imaging endoscopy clearly distinguishes histological and serological severity of chronic gastritis. Gastrointest Endosc: 2009; 70 246 253
69. Bansal A, Ulusarac O, Mathur S et al. Correlation between narrow band imaging and nonneoplastic gastric pathology: a pilot feasibility trial. Gastrointest Endosc: 2008; 67 210 216
70. Kato M, Kaise M, Yonezawa J et al. Magnifying endoscopy with narrow-band imaging achieves superior accuracy in the differential diagnosis of superficial gastric lesions identified with white-light endoscopy: a prospective study. Gastrointest Endosc: 2010; 72 523 529
71. Ezoe Y, Muto M, Horimatsu T et al. Magnifying narrow-band imaging versus magnifying white-light imaging for the differential diagnosis of gastric small depressive lesions: a prospective study. Gastrointest Endosc: 2010; 71 477 484
72. Kadowaki S, Tanaka K, Toyoda H et al. Ease of early gastric cancer demarcation recognition: a comparison of four magnifying endoscopy methods. J Gastroenterol Hepatol: 2009; 24 1625 1630
73. Uedo N, Ishihara R, Iishi H et al. A new method of diagnosing gastric intestinal metaplasia: narrow-band imaging with magnifying endoscopy. Endoscopy: 2006; 38 819 824 (Pubitemid 44314637)
74. Okubo M, Tahara T, Shibata T et al. Changes in gastric mucosal patterns seen by magnifying NBI during H. pylori eradication. J Gastroenterol: 2011; 46 175 182
75. Kaise M, Kato M, Urashima M et al. Magnifying endoscopy combined with narrow-band imaging for differential diagnosis of superficial depressed gastric lesions. Endoscopy: 2009; 41 310 315
76. Capelle LG, Haringsma J, da Vries AC et al. Narrow band imaging for the detection of gastric intestinal metaplasia and dysplasia during surveillance endoscopy. Dig Dis Sci: 2010; 55 3442 3448
77. Alaboudy AA, Elbahrawy A, Matsumoto S et al. Conventional narrow-band imaging has good correlation with histopathological severity of Helicobacter pylori gastritis. Dig Dis Sci: 2011; 56 1127 1130
78. Eriksson NK, Frkkil MA, Voutilainen ME et al. The clinical value of taking routine biopsies from the incisura angularis during gastroscopy. Endoscopy: 2005; 37 532 536 (Pubitemid 40775236)
79. Guarner J, Herrera-Goepfert R, Mohar A et al. Diagnostic yield of gastric biopsy specimens when screening for preneoplastic lesions. Hum Pathol: 2003; 34 28 31 (Pubitemid 36160018)
80. el-Zimaity HM, Graham DY. Evaluation of gastric mucosal biopsy site and number for identification of Helicobacter pylori or intestinal metaplasia: role of the Sydney System. Hum Pathol: 1999; 30 72 77 (Pubitemid 29037397)
81. Rugge M, Genta RM. Staging and grading of chronic gastritis. Hum Pathol: 2005; 36 228 233 (Pubitemid 40404005)
82. Kashin S, Pavlov A, Gono K, Nadezhin A. Endoscopic diagnosis of early gastric cancer and gastric precancerous lesions. In: Pasechnikov VD. ed. Gastric cancer: diagnosis, early prevention, and treatment. 1 edn. New York Nova Science Publishers XXXHauppauge?XXX: 2010; 197 233
83. Satoh K, Kimura K, Taniguchi Y et al. Biopsy sites suitable for the diagnosis of Helicobacter pylori infection and the assessment of the extent of atrophic gastritis. Am J Gastroenterol: 1998; 93 569 573 (Pubitemid 29081004)
84. de Vries AC, Haringsma J, de Vries RA et al. Biopsy strategies for endoscopic surveillance of pre-malignant gastric lesions. Helicobacter: 2010; 15 259 264
85. Rugge M, Cassaro M, Pennelli G et al. Atrophic gastritis: pathology and endoscopy in the reversibility assessment. Gut: 2003; 52 1387 1388 (Pubitemid 37026482)
86. Ricuarte O, Gutierrez O, Cardona H et al. Atrophic gastritis in young children and adolescents. J Clin Pathol: 2005; 58 1189 1193 (Pubitemid 41566465)
87. You WC, Blot WJ, Li JY et al. Precancerous gastric lesions in a population at high risk of stomach cancer. Cancer Res: 1993; 53 1317 1321 (Pubitemid 23097109)
88. Dursun M, Yilmaz S, Ykselen V et al. Evaluation of optimal gastric mucosal biopsy site and number for identification of Helicobacter pylori, gastric atrophy and intestinal metaplasia. Hepatogastroenterology: 2004; 51 1732 1735 (Pubitemid 39389769)
89. el-Zimaity HM, al-Assi MT, Genta RM et al. Confirmation of successful therapy of Helicobacter pylori infection: number and site of biopsies or a rapid urease test. Am J Gastroenterol: 1995; 90 1962 1964
90. el-Zimaity HM, Ota H, Graham DY et al. Patterns of gastric atrophy in intestinal type gastric carcinoma. Cancer: 2002; 94 1428 1436 (Pubitemid 34212636)
91. el-Zimaity HM, Ramchatesingh J, Saeed MA et al. Gastric intestinal metaplasia: subtypes and natural history. J Clin Pathol: 2001; 54 679 683 (Pubitemid 32835414)
92. Rugge M, Correa P, Di Mario F et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis: 2008; 40 650 658
93. Rugge M, Genta RM. OLGA groupe Staging gastritis: an international proposal. Gastroenterology: 2005; 129 1807 1808
94. Rugge M, Meggio A, Pennelli G et al. Gastritis staging in clinical practice: the OLGA staging system. Gut: 2007; 56 631 636 (Pubitemid 46662927)
95. Satoh K, Osawa H, Yoshizawa M et al. Assessment of atrophic gastritis using the OLGA system. Helicobacter: 2008; 13 225 229 (Pubitemid 351667074)
96. Rugge M, de Boni M, Pennelli G et al. Gastritis OLGA-staging and gastric cancer risk: a twelve year clinico-pathological follow-up study. Aliment Pharmacol Ther: 2010; 31 1104 1111
97. el-Zimaity HM, Graham DY, al-Assi MT et al. Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis. Hum Pathol: 1996; 27 35 41 (Pubitemid 26015579)
98. Capelle LG, de Vries AC, Haringsma J et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc: 2010; 71 1150 1158
99. Guarner J, Herrera-Goepfert R, Mohar A et al. Interobserver variability in application of the revised Sydney classification for gastritis. Hum Pathol: 1999; 30 1431 1434 (Pubitemid 30032918)
100. Dinis-Ribeiro M, Yamaki G, Miki K et al. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen: 2004; 11 141 147 (Pubitemid 39274096)
101. Graham DY, Nurgalieva ZZ, El-Zimaity HM et al. Noninvasive versus histologic detection of gastric atrophy in a Hispanic population in North America. Clin Gastroenterol Hepatol: 2006; 4 306 314 (Pubitemid 43343886)
102. Haj-Sheykholeslami A, Rakhshani N, Amirzargar A et al. Serum pepsinogen I, pepsinogen II, and gastrin 17 in relatives of gastric cancer patients: comparative study with type and severity of gastritis. Clin Gastroenterol Hepatol: 2008; 6 174 179 (Pubitemid 351172947)
103. Hartleb M, Wandzel P, Waluga M et al. Non-endoscopic diagnosis of multifocal atrophic gastritis; efficacy of serum gastrin-17, pepsinogens and Helicobacter pylori antibodies. Acta Gastroenterol Belg: 2004; 67 320 326 (Pubitemid 40188052)
104. Iijima K, Abe Y, Kikuchi R et al. Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach. World J Gastroenterol: 2009; 15 853 859
105. Inoue M, Kobayashi S, Matsuura A et al. Agreement of endoscopic findings and serum pepsinogen levels as an indicator of atrophic gastritis. Cancer Epidemiol Biomarkers Prev: 1998; 7 261 263 (Pubitemid 28353939)
106. Kim HY, Kim N, Kang JN et al. Clinical meaning of pepsinogen test and Helicobacter pylori serology in the health check-up population in Korea. Eur J Gastroenterol Hepatol: 2009; 21 606 612
107. Knight T, Wyatt J, Wilson A et al. Helicobacter pylori gastritis and serum pepsinogen levels in a healthy population: development of a biomarker strategy for gastric atrophy in high risk groups. Br J Cancer: 1996; 73 819 824 (Pubitemid 26105313)
108. Leja M, Kupcinkas L, Funka K et al. The validity of a biomarker method for indirect detection of gastric mucosal atrophy versus standard histopathology. Dig Dis Sci: 2009; 54 2377 2384
109. Ley C, Mohar A, Guarner J et al. Screening markers for chronic atrophic gastritis in Chiapas, Mexico. Cancer Epidemiol Biomarkers Prev: 2001; 10 107 112 (Pubitemid 32172428)
110. Nardone G, Rocco A, Staibano S et al. Diagnostic accuracy of the serum profile of gastric mucosa in relation to histological and morphometric diagnosis of atrophy. Aliment Pharmacol Ther: 2005; 22 1139 1146 (Pubitemid 41779522)
111. Pasechnikov VD, Chukov SZ, Kotelevets SM et al. Invasive and non-invasive diagnosis of Helicobacter pylori-associated atrophic gastritis: a comparative study. Scand J Gastroenterol: 2005; 40 297 301 (Pubitemid 40476460)
112. Ricci C, Vakil N, Rugge M et al. Serological markers for gastric atrophy in asymptomatic patients infected with Helicobacter pylori. Am J Gastroenterol: 2004; 99 1910 1915 (Pubitemid 39421232)
113. Rollan A, Ferreccio C, Gederlini A et al. Noninvasive diagnosis of gastric mucosal atrophy in an asymptomatic population with high prevalence of gastric cancer. World J Gastroenterol: 2006; 12 7172 7178 (Pubitemid 44890649)
114. Sierra R, Une C, Ramrez V et al. Association of serum pepsinogen with atrophic body gastritis in Costa Rica. Clin Exp Med: 2006; 6 72 78
115. Sitas F, Smallwood R, Jewell D et al. Serum anti-Helicobacter pylori IgG antibodies and pepsinogens A and C as serological markers of chronic atrophic gastritis. Cancer Epidemiol Biomarkers Prev: 1993; 2 119 123
116. Storskrubb T, Aro P, Ronkainen J et al. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: the Kalixanda study. Scand J Gastroenterol: 2008; 43 1448 1455
117. Sun LP, Gong YH, Wang L et al. Serum pepsinogen levels and their influencing factors: a population-based study in 6990 Chinese from North China. World J Gastroenterol: 2007; 13 6562 6567
118. Wu KC, Li HT, Qiao TD et al. Diagnosis of atrophic body gastritis in Chinese patients by measuring serum pepsinogen. Chin J Dig Dis: 2004; 5 22 27 (Pubitemid 38401246)
119. Vnnen H, Vauhkonen M, Helske T et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol: 2003; 15 885 891 (Pubitemid 36904458)
120. Cao Q, Ran ZH, Xiao SD. Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Helicobacter pylori immunoglobulin G antibodies. J Dig Dis: 2007; 8 15 22 (Pubitemid 46189205)
121. Chung HW, Kim JW, Lee JH et al. Comparison of the validity of three biomarkers for gastric cancer screening: carcinoembryonic antigen, pepsinogens, and high sensitive C-reactive protein. J Clin Gastroenterol: 2009; 43 19 26
122. Kiyohira K, Yoshihara M, Ito M et al. Serum pepsinogen concentration as a marker of Helicobacter pylori infection and the histologic grade of gastritis: evaluation of gastric mucosa by serum pepsinogen levels. J Gastroenterol: 2003; 38 332 338 (Pubitemid 36626268)
123. Oksanen A, Sipponen P, Miettinen A et al. Evaluation of blood tests to predict normal gastric mucosa. Scand J Gastroenterol: 2000; 35 791 795
124. Di Mario F, Cavallar LG, Moussa AM et al. Usefulness of serum pepsinogens in Helicobacter pylori chronic gastritis: relationship with inflammation, activity, and density of the bacterium. Dig Dis Sci: 2006; 51 1791 1795 (Pubitemid 44546748)
125. Kreuning J, Lindeman J, Biemond I et al. Serological parameters in assessment of degree of gastritis in healthy volunteers. Dig Dis Sci: 1995; 40 609 614
126. Con SA, Con-Wong R, Con-Chin GR et al. Serum pepsinogen levels, Helicobacter pylori CagA status, and cytokine gene polymorphisms associated with gastric premalignant lesions in Costa Rica. Cancer Epidemiol Biomarkers Prev: 2007; 16 2631 2636 (Pubitemid 351196318)
127. Dinis-Ribeiro M, da Costa-Pereira A, Lopes C et al. Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma. Neoplasia: 2004; 6 449 456 (Pubitemid 39411081)
128. Urita Y, Hike K, Torii N et al. Serum pepsinogens as a predicator of the topography of intestinal metaplasia in patients with atrophic gastritis. Dig Dis Sci: 2004; 49 795 801 (Pubitemid 38870206)
129. de Vries AC, Haringsma J, de Vries RA et al. The use of clinical, histologic, and serologic parameters to predict the intragastric extent of intestinal metaplasia: a recommendation for routine practice. Gastrointest Endosc: 2009; 70 18 25
130. Watabe H, Mitsushima T, Yamaji Y et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut: 2005; 54 764 768 (Pubitemid 40732089)
131. Yamaji Y, Watabe H, Yoshida H et al. High-risk population for gastric cancer development based on serum pepsinogen status and lifestyle factors. Helicobacter: 2009; 14 81 86
132. Yanaoka K, Oka M, Mukoubayashi C et al. Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol Biomarkers Prev: 2008; 17 838 845 (Pubitemid 351536414)
133. Yanaoka K, Oka M, Yoshimura N et al. Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels. Int J Cancer: 2008; 123 917 926 (Pubitemid 352032422)
134. Ohata H, Kitauchi S, Yoshimura N et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer: 2004; 109 138 143 (Pubitemid 38160674)
135. Oishi Y, Kiyohara Y, Kubo M et al. The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. Am J Epidemiol: 2006; 163 629 637
136. Dinis-Ribeiro M, da Costa-Pereira A, Lopes C et al. Feasibility and cost-effectiveness of using magnification chromoendoscopy and pepsinogen serum levels for the follow-up of patients with atrophic chronic gastritis and intestinal metaplasia. J Gastroenterol Hepatol: 2007; 22 1594 1604 (Pubitemid 47383332)
137. Miki K, Fujishiro M, Kodashima S et al. Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population. Dig Endosc: 2009; 21 78 81
138. Aromaa A, Kosunen TU, Knekt P et al. Circulating anti-Helicobacter pylori immunoglobulin A antibodies and low serum pepsinogen I level are associated with increased risk of gastric cancer. Am J Epidemiol: 1996; 144 142 149 (Pubitemid 26234992)
139. Fukuda H, Saito D, Hayashi S et al. Helicobacter pylori infection, serum pepsinogen level and gastric cancer: a casecontrol study in Japan. Jpn J Cancer Res: 1995; 86 64 71
140. Kikuchi S, Wada O, Miki K et al. Serum pepsinogen as a new marker for gastric carcinoma among young adults. Research Group on Prevention of Gastric Carcinoma among Young Adults. Cancer: 1994; 73 2695 2702 (Pubitemid 24166253)
141. Knekt P, Teppo L, Aromaa A et al. Helicobacter pylori IgA and IgG antibodies, serum pepsinogen I and the risk of gastric cancer: changes in the risk with extended follow-up period. Int J Cancer: 2006; 119 702 705 (Pubitemid 43955726)
142. Kodoi A, Yoshihara M, Sumii K et al. Serum pepsinogen in screening for gastric cancer. J Gastroenterol: 1995; 30 452 460
143. Kokkola A, Louhimo J, Puolakkainen P et al. Helicobacter pylori infection and low serum pepsinogen I level as risk factors for gastric carcinoma. World J Gastroenterol: 2005; 11 1032 1036 (Pubitemid 40347758)
144. Kwak MS, Kim N, Lee HS et al. Predictive power of serum pepsinogen tests for the development of gastric cancer in comparison to the histologic risk index. Dig Dis Sci: 2010; 55 2275 2282
145. Miki K, Ichinose M, Kawamura N et al. The significance of low serum pepsinogen levels to detect stomach cancer associated with extensive chronic gastritis in Japanese subjects. Jpn J Cancer Res: 1989; 80 111 114 (Pubitemid 20027662)
146. Nomura AM, Stemmermann GN, Samloff IM. Serum pepsinogen I as a predictor of stomach cancer. Ann Intern Med: 1980; 93 537 540 (Pubitemid 10015174)
147. Parsonnet J, Samloff IM, Nelson LM et al. Helicobacter pylori, pepsinogen, and risk for gastric adenocarcinoma. Cancer Epidemiol Biomarkers Prev: 1993; 2 461 466
148. Parthasarathy G, Maroju NK, Kate V et al. Serum pepsinogen I and II levels in various gastric disorders with special reference to their use as a screening test for carcinoma stomach. Trop Gastroenterol: 2007; 28 166 170
149. Ren JS, Kamangar F, Qiao YL et al. Serum pepsinogens and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort. Gut: 2009; 58 636 642
150. Sasazuki S, Inoue M, Iwasaki M. et al. Japan Public Health Center Study Group Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested casecontrol study. Cancer Epidemiol Biomarkers Prev: 2006; 15 1341 1347 (Pubitemid 44125292)
151. Shiotani A, Iishi H, Uedo N et al. Histologic and serum risk markers for noncardia early gastric cancer. Int J Cancer: 2005; 115 463 469 (Pubitemid 40663752)
152. So JB, Yeoh KG, Moochala S et al. Serum pepsinogen levels in gastric cancer patients and their relationship with Helicobacter pylori infection: a prospective study. Gastric Cancer: 2002; 5 228 232 (Pubitemid 36605886)
153. Sugiu K, Kamada T, Ito M et al. Anti-parietal cell antibody and serum pepsinogen assessment in screening for gastric carcinoma. Dig Liver Dis: 2006; 38 303 307 (Pubitemid 44382356)
154. Yoshihara M, Hiyama T, Yoshida S et al. Reduction in gastric cancer mortality by screening based on serum pepsinogen concentration: a casecontrol study. Scand J Gastroenterol: 2007; 42 760 764 (Pubitemid 46763575)
155. Hattori Y, Tashiro H, Kawamoto T et al. Sensitivity and specificity of mass screening for gastric cancer using the measurment of serum pepsinogens. Jpn J Cancer Res: 1995; 86 1210 1215
156. Kitahara F, Kobayashi K, Sato T et al. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut: 1999; 44 693 697 (Pubitemid 29195918)
157. Westerveld BD, Pals G, Lamers CB et al. Clinical significance of pepsinogen A isozymogens, serum pepsinogen A and C levels, and serum gastrin levels. Cancer: 1987; 59 952 958 (Pubitemid 17024651)
158. You WC, Blot WJ, Zhang L et al. Serum pepsinogens in relation to precancerous gastric lesions in a population at high risk for gastric cancer. Cancer Epidemiol Biomarkers Prev: 1993; 2 113 117
159. Yoshihara M, Sumii K, Haruma K et al. Correlation of ratio of serum pepsinogen I and II with prevalence of gastric cancer and adenoma in Japanese subjects. Am J Gastroenterol: 1998; 93 1090 1096 (Pubitemid 29080956)
160. Miki K, Ichinose M, Ishikawa KB et al. Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer. Jpn J Cancer Res: 1993; 84 1086 1090 (Pubitemid 23307845)
161. Miki K, Morita M, Sasajima M et al. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol: 2003; 98 735 739 (Pubitemid 36576295)
162. Pharoah PD, Guilford P, Caldas C. International Gastric Cancer Linkage Consortium Incidence of gastric cancer and breast cancer in CDH1 (Ecadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology: 2001; 121 1348 1353 (Pubitemid 33140452)
163. Fitzgerald RC, Hardwick R, Huntsman D et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet: 2010; 47 436 444
164. Watson P, Vasen HF, Mecklin JP et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer: 2008; 123 444 449 (Pubitemid 351842032)
165. Capelle LG, Van Grieken NC, Lingsma HF et al. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology: 2010; 138 487 492
166. Giardiello FM, Brensinger JD, Tersmette AC et al. Very high risk of cancer in familial PeutzJeghers syndrome. Gastroenterology: 2000; 119 1447 1453 (Pubitemid 32198669)
167. van Lier MG, Westerman AM, Wagner A et al. High cancer risk and increased mortality in patients with PeutzJeghers syndrome. Gut: 2011; 60 141 147
168. Offerhaus GJ, Giardiello FM, Krush AJ et al. The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology: 1992; 102 1980 1982
169. Yaghoobi M, Bijarchi R, Narod SA. Family history and the risk of gastric cancer. Br J Cancer: 2009; 102 237 242
170. Bakir T, Can G, Erkul S et al. Stomach cancer history in the siblings of patients with gastric carcinoma. Eur J Cancer Prev: 2000; 9 401 408 (Pubitemid 32065953)
171. La Vecchia C, Negri E, Franceschi S et al. Family history and the risk of stomach and colorectal cancer. Cancer: 1992; 70 50 55
172. Palli D, Galli M, Caporaso NE et al. Family history and risk of stomach cancer in Italy. Cancer Epidemiol Biomarkers Prev: 1994; 3 15 18 (Pubitemid 24172516)
173. Garca-Gonzlez MA, Lanas A, Quintero E et al. Gastric cancer susceptibility is not linked to pro- and anti-inflammatory cytokine gene polymorphisms in whites: a nationwide multicenter study in Spain. Am J Gastroenterol: 2007; 102 1878 1892 (Pubitemid 47301539)
174. Dhillon PK, Farrow DC, Vaughan TL et al. Family history of cancer and risk of esophageal and gastric cancers in the United States. Int J Cancer: 2001; 93 148 152 (Pubitemid 32544602)
175. Minami Y, Tateno H. Associations between cigarette smoking and the risk of four leading cancers in Miyagi Prefecture, Japan: a multi-site casecontrol study. Cancer Sci: 2003; 94 540 547 (Pubitemid 36849720)
176. Eto K, Ohyama S, Yamaguchi T et al. Familial clustering in subgroups of gastric cancer stratified by histology, age group and location. Eur J Sur Oncol: 2006; 32 743 748 (Pubitemid 44276008)
177. Hong SH, Kim JW, Kim HG et al. Glutathione S-transferases (GSTM1, GSTT1 and GSTP1) and N-acetyltransferase 2 polymorphisms and the risk of gastric cancer. J Prev Med Public Health: 2006; 39 135 140
178. Foschi R, Lucenteforte E, Bosetti C et al. Family history of cancer and stomach cancer risk. Int J Cancer: 2008; 123 1429 1432
179. Bernini M, Barbi S, Roviello F et al. Family history of gastric cancer: a correlation between epidemiologic findings and clinical data. Gastric Cancer: 2006; 9 9 13
180. Rokkas T, Sechopoulos P, Pistiolas D et al. Helicobacter pylori infection and gastric histology in firstdegree relatives of gastric cancer patients: a meta-analysis. Eur J Gastroenterol Hepatol: 2010; 22 1128 1133
181. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans Lyon, 714 June 1994. IARC Monogr Eval Carcinog Risks Hum: 1994; 61 1 241
182. Figueiredo C, Machado JC, Pharoah P et al. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst: 2002; 94 1680 1687 (Pubitemid 35446836)
183. Amieva MR, El-Omar EM. Hostbacterial interactions in Helicobacter pylori infection. Gastroenterology: 2008; 134 306 323 (Pubitemid 350309334)
184. Machado JC, Figueiredo C, Canedo P et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology: 2003; 125 364 371 (Pubitemid 36929416)
185. Huang JQ, Zheng GF, Sumanac K et al. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology: 2003; 125 1636 1644 (Pubitemid 37500427)
186. Basso D, Zambon CF, Letley DP et al. Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology: 2008; 135 91 99 (Pubitemid 351899019)
187. El-Omar EM, Carrington M, Chow WH. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature: 2000; 404 398 402 (Pubitemid 30164342)
188. Yin M, Hu Z, Tan D et al. Molecular epidemiology of genetic susceptibility to gastric cancer: focus on single nucleotide polymorphisms in gastric carcinogenesis. Am J Transl Res: 2009; 1 44 54
189. Persson C, Canedo P, Machado JC et al. Polymorphisms in inflammatory response genes and their association with gastric cancer: A a HuGE systematic review and meta-analyses. Am J Epidemiol: 2011; 173 259 270
190. Wang P, Xia HH, Zhang JY et al. Association of interleukin-1 gene polymorphisms with gastric cancer: a meta-analysis. Int J Cancer: 2007; 120 552 562 (Pubitemid 44969026)
191. Camargo MC, Mera R, Correa P et al. Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer: a metaanalysis. Cancer Epidemiol Biomarkers Prev: 2006; 15 1674 1687 (Pubitemid 44497104)
192. Xue H, Lin B, Ni P et al. Interleukin-1B and interleukin-1 RN polymorphisms and gastric carcinoma risk: a meta-analysis. J Gastroenterol Hepatol: 2010; 25 1604 1617
193. Kamangar F, Cheng C, Abnet CC et al. Interleukin-1B polymorphisms and gastric cancer risk a meta-analysis. Cancer Epidemiol Biomarkers Prev: 2006; 15 1920 1928 (Pubitemid 44664269)
194. Loh M, Koh KX, Yeo BH et al. Meta-analysis of genetic polymorphisms and gastric cancer risk: variability in associations according to race. Eur J Cancer: 2009; 45 2562 2568
195. Schlemper RJ, Riddell RH, Kato Y et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut: 2000; 47 251 255 (Pubitemid 30489769)
196. Rugge M, Leandro G, Farinati F et al. Gastric epithelial dysplasia. How clinicopathologic background relates to management. Cancer: 1995; 76 376 382
197. Rugge M, Cassaro M, Di Mario F. et al. Interdisciplinary Group on Gastric Epithelial Dysplasia (IGGED) The long term outcome of gastric non-invasive neoplasia. Gut: 2003; 52 1111 1116 (Pubitemid 36877421)
198. de Jonge PJ, van Blankenstein M, Looman CW et al. Risk of malignant progression in patients with Barretts oesophagus: a Dutch nationwide cohort study. Gut: 2010; 59 1030 1036
199. Stryker SJ, Wolff BG, Culp CE et al. Natural history of untreated colonic polyps. Gastroenterology: 1987; 93 1009 1013 (Pubitemid 18000643)
200. Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther: 2003; 18 02 1 5 (Pubitemid 37174709)
201. Weinstein WM, Goldstein N. Gastric dysplasia and its management. Gastroenterology: 1994; 107 1543 1559
202. Ching CK. Can we justify resecting all gastric epithelial dysplastic lesions? Gastroenterology: 1995; 108 1955 1956
203. Abraham SC, Montgomery EA, Singh VK et al. Gastric adenomas: intestinal type and gastric type adenomas differ in the risk of adenocarcinoma and presence of background mucosal pathology. Am J Surg Pathol: 2000; 26 1276 1285
204. Hosokawa O, Watanabe K, Hatorri M et al. Detection of gastric cancer by repeat endoscopy within a short time after negative examination. Endoscopy: 2001; 33 301 305 (Pubitemid 32586418)
205. de Dombal FT, Price AB, Thompson H et al. The British Society of Gastroenterology early gastric cancer/dysplasia survey: an interim report. Gut: 1990; 31 115 120 (Pubitemid 20037992)
206. Sipponen P, Kekki M, Siurali M. Atrophic chronic gastritis and intestinal metaplasia in gastric cancer: comparison with a representative population sample. Cancer: 1983; 52 1062 1068 (Pubitemid 13050773)
207. Hull MJ, Mino-Kenudson M, Nishioka NS et al. Endoscopic mucosal resection: an improved diagnostic procedure for early gastroesophageal epithelial neoplasms. Am J Surg Pathol: 2006; 30 114 118 (Pubitemid 43740217)
208. Kim YJ, Park JC, Kim JH et al. Histologic diagnosis based on forceps biopsy is not adequate for determining endoscopic treatment of gastric adenomatous lesions. Endoscopy: 2010; 42 620 626
209. Kim ES, Jeon SW, Park SY et al. Where has the tumor gone? The characteristics of cases of negative pathologic diagnosis after endoscopic mucosal resection. Endoscopy: 2009; 41 739 745
210. Cassaro M, Rugge M, Gutierrez O et al. Topographic patterns of intestinal metaplasia and gastric cancer. Am J Gastroenterol: 2000; 95 1431 1438 (Pubitemid 30396299)
211. Morson BC. Carcinoma arising from areas of intestinal metaplasia in the gastric mucosa. Br J Cancer: 1955; 9 377 385
212. Vannella L, Lahner E, Osborn J et al. Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis. Aliment Pharmacol Ther: 2010; 31 1042 1050
213. Lahner E, Bordi C, Cattaruzza MS et al. Long-term follow-up in atrophic body gastritis patients: atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection. Aliment Pharmacol Ther: 2005; 22 471 481 (Pubitemid 41248115)
214. Van Zanten SJ, Dixon MF, Lee A. The gastric transitional zones: neglected links between gastroduodenal pathology and helicobacter ecology. Gastroenterology: 1999; 116 1217 1229 (Pubitemid 29203032)
215. Kimura A, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy: 1969; 1 87 97
216. Rokkas T, Filipe MI, Sladen GE. Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut: 1991; 32 1110 1113
217. Tosi P, Filipe MI, Luzi P et al. Gastric intestinal metaplasia type III cases are classified as low-grade dysplasia on the basis of morphometry. J Pathol: 1993; 169 73 78 (Pubitemid 23034426)
218. Ramesar KC, Sanders DS, Hopwood D. Limited value of type III intestinal metaplasia in predicting risk of gastric carcinoma. J Clin Pathol: 1987; 40 1287 1290 (Pubitemid 18015256)
219. Conchillo JM, Houben G, de Brune A et al. Is type III intestinal metaplasia an obligatory precancerous lesion in intestinal-type gastric carcinoma? Eur J Cancer Prev: 2001; 10 307 312 (Pubitemid 32735346)
220. Nozaki K, Shimizu N, Ikehara Y et al. Effect of early eradication on Helicobacter pylori-related gastric carcinogenesis in Mongolian gerbils. Cancer Sci: 2003; 94 235 239 (Pubitemid 36575888)
221. Shimizu N, Ikehara Y, Inada K et al. Eradication diminishes enhancing effects of Helicobacter pylori infection on glandular stomach carcinogenesis in Mongolian gerbils. Cancer Res: 2000; 60 1512 1514 (Pubitemid 30183416)
222. Maruta F, Sugiyama A, Ishizone S et al. Eradication of Helicobacter pylori decreases mucosal alterations linked to gastric carcinogenesis in Mongolian gerbils. J Gastroenterol: 2005; 40 104 105 (Pubitemid 40796340)
223. Pimanov SI, Makarenko EV, Voropaeva AV et al. Helicobacter pylori eradication improves gastric histology and decreases serum gastrin, pepsinogen I and pepsinogen II levels in patients with duodenal ulcer. J Gastroenterol Hepatol: 2008; 23 1666 1671
224. Rokkas T, Pistiolas D, Sechopoulos P et al. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter: 2007; 12 02 32 38 (Pubitemid 350076224)
225. de Vries AC, Kuipers EJ. Review article: Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther: 2007; 26 02 25 35 (Pubitemid 350233320)
226. Wang J, Xu L, Shi R et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion: 2011; 83 253 260
227. Annibale B, Aprile MR, Dambra G et al. Cure of Helicobacter pylori infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECL-cell hyperplasia. Aliment Pharmacol Ther: 2000; 14 625 634 (Pubitemid 30240756)
228. Satoh K, Kimura K, Takimoto T et al. A follow-up study of atrophic gastritis and intestinal metaplasia after eradication of Helicobacter pylori. Helicobacter: 1998; 3 236 240 (Pubitemid 128656775)
229. Correa P, Fontham ET, Bravo JC et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst: 2000; 92 1881 1888 (Pubitemid 32036918)
230. Mera R, Fontham ET, Bravo LE et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut: 2005; 54 1536 1540 (Pubitemid 41531767)
231. Wong BC, Lam SK, Wong WM. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA: 2004; 291 187 194 (Pubitemid 38082812)
232. Fuccio L, Zagari RM, Minardi ME et al. Systematic review: Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther: 2007; 25 133 141 (Pubitemid 46046370)
233. Fuccio L, Zagari RM, Eusebi LH et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med: 2009; 151 121 128
234. Kim N, Park RY, Cho SI et al. Helicobacter pylori infection and development of gastric cancer in Korea: long-term follow-up. J Clin Gastroenterol: 2008; 42 448 454 (Pubitemid 351572254)
235. Leung WK, Lin SR, Ching JY et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut: 2004; 53 1244 1249 (Pubitemid 39120105)
236. You WC, Brown LM, Zhang L et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst: 2006; 98 974 983 (Pubitemid 44288162)
237. Take S, Mizuno M, Ishiki K et al. The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol: 2005; 100 1037 1042 (Pubitemid 40769039)
238. Take S, Mizuno M, Ishiki K et al. The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori. J Gastroenterol: 2011; 46 318 324
239. Fukase K, Kato M, Kikuchi S et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet: 2008; 372 392 397
240. Uemura N, Mukai T, Okamoto S et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev: 1997; 6 639 642 (Pubitemid 27342688)
241. Toyokawa T, Suwaki K, Miyake Y et al. Eradication of Helicobacter pylori infection improved gastric mucosal atrophy and prevented progression of intestinal metaplasia, especially in the elderly population: a long-term prospective cohort study. J Gastroenterol Hepatol: 2010; 25 544 547
242. Yang HB, Sheu BS, Wang ST et al. H. pylori eradication prevents the progression of gastric intestinal metaplasia in reflux esophagitis patients using long-term esomeprazole. Am J Gastroenterol: 2009; 104 1642 1649
243. Malfertheiner P, Megraud F, OMorain C et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut: 2007; 56 772 781 (Pubitemid 46854190)
244. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol: 1998; 13 1 12 (Pubitemid 28137751)
245. Malfertheiner P, Mgraud F, OMorain C. et al. European Helicobacter Pylori Study Group (EHPSG) Current concepts in the management of Helicobacter pylori infection the Maastricht 22000 Consensus Report. Aliment Pharmacol Ther: 2002; 16 167 180 (Pubitemid 34146357)
246. Fock KM, Katelaris P, Sugano K. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol: 2009; 24 1587 1600
247. Shin DW, Yun YH, Choi IJ et al. Costeffectiveness of eradication of Helicobacter pylori in gastric cancer survivors after endoscopic resection of early gastric cancer. Helicobacter: 2009; 14 536 544
248. Wang WH, Huang JQ, Zheng GF et al. Nonsteroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst: 2003; 95 1784 1791 (Pubitemid 38008901)
249. Tian W, Zhao Y, Liu S et al. Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer. Eur J Cancer Prev: 2010; 19 288 298
250. Leung WK, Ng EK, Chan FK et al. Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial. Clin Cancer Res: 2006; 12 4766 4772 (Pubitemid 44297831)
251. Zhang LJ, Wang SY, Huo XH et al. Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions. World J Gastroenterol: 2009; 15 2731 2738
252. Hung KH, Yang HB, Cheng HC et al. Short-term celecoxib to regress long-term persistent gastric intestinal metaplasia after Helicobacter pylori eradication. J Gastroenterol Hepatol: 2010; 25 48 53
253. Yanaoka K, Oka M, Yoshimura N et al. Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. Int J Cancer: 2010; 126 1467 1473
254. Yang HB, Cheng HC, Sheu BS et al. Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication. Aliment Pharmacol Ther: 2007; 25 455 461
255. Wu CY, Wu MS, Kuo KN et al. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. J Clin Oncol: 2010; 28 2952 2957
256. Plummer M, Vivas J, Lopez G et al. Chemoprevention of precancerous gastric lesions with antioxidant vitamin supplementation: a randomized trial in a high-risk population. J Natl Cancer Inst: 2007; 99 137 146
257. Mason J, Axon AT, Forman D et al. The costeffectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. Aliment Pharmacol Ther: 2002; 16 559 568 (Pubitemid 34214537)
258. Parsonnet J, Harris RA, Hack HM et al. Modelling costeffectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet: 1996; 348 150 154 (Pubitemid 26238097)
259. Davies R, Crabbe D, Roderick P et al. A simulation to evaluate screening for Helicobacter pylori infection in the prevention of peptic ulcers and gastric cancers. Health Care Manag Sci: 2002; 5 249 258 (Pubitemid 41450970)
260. Roderick P, Davies R, Raftery J et al. The costeffectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model. Health Technol Assess: 2003; 7 1 86
261. Roderick P, Davies R, Raftery J et al. Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation. J Med Screen: 2003; 10 148 156 (Pubitemid 38296852)
262. Leivo T, Salomaa A, Kosunen TU et al. Costbenefit analysis of Helicobacter pylori screening. Health Policy: 2004; 70 85 96 (Pubitemid 39092961)
263. Dan YY, So JB, Yeoh KG. Endoscopic screening for gastric cancer. Clin Gastroenterol Hepatol: 2006; 4 709 716 (Pubitemid 43825816)
264. Yeh JM, Kuntz KM, Ezzati M et al. Exploring the costeffectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. Int J Cancer: 2009; 124 157 166
265. Lee YC, Lin JT, Wu HM et al. Costeffectiveness analysis between primary and secondary preventive strategies for gastric cancer. Cancer Epidemiol Biomarkers Prev: 2007; 16 875 885
266. Lee HY, Park EC, Jun JK et al. Comparing upper gastrointestinal X-ray and endoscopy for gastric cancer diagnosis in Korea. World J Gastroenterol: 2010; 16 245 250
267. Xie F, Luo N, Blackhouse G et al. Costeffectiveness analysis of Helicobacter pylori screening in prevention of gastric cancer in Chinese. Int J Technol Assess Health Care: 2008; 24 87 95 (Pubitemid 351158547)
268. Xie F, Luo N, Lee HP. Cost effectiveness analysis of population-based serology screening and 13C-urea breath test for Helicobacter pylori to prevent gastric cancer: a markov model. World J Gastroenterol: 2008; 14 3021 3027
269. Fendrick AM, Chernew ME, Hirth RA et al. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Arch Intern Med: 1999; 159 142 148 (Pubitemid 29055101)
270. Yeh JM, Hur C, Kuntz KM et al. Costeffectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer. Cancer: 2010; 116 2941 2953
271. Hassan C, Zullo A, Di Giulio E et al. Costeffectiveness of endoscopic surveillance for gastric intestinal metaplasia. Helicobacter: 2010; 15 221 226